REFERENSI

1. Air Pollution [Internet]. World Health Organization; Available from: https://www.who.int/health-topics/air-pollution#tab=tab_1
2. Istiqomah NA, Marleni NN. Particulate Air Pollution in Indonesia: Quality index, characteristic, and source identification. IOP Conference Series: Earth and Environmental Science. 2020 Nov 1;599(1):012084. doi:10.1088/1755-1315/599/1/012084
3. Indeks Kualitas Udara (AQI) Kabupaten Tangerang Curug dan Polusi Udara di Curug [Internet]. Available from: http://www.iqair.com/id/indonesia/banten/curug/kabupaten-tangerang-curug
4. Indeks Kualitas Udara (AQI) Kabupaten Tangerang dan Polusi Udara di Cikupa [Internet]. Available from: http://www.iqair.com/id/indonesia/west-java/cikupa/kabupaten-tangerang
5. Li T, Hu R, Chen Z, Li Q, Huang S, Zhu Z, et al. Fine particulate matter (PM2.5): The culprit for chronic lung diseases in China. Chronic Diseases and Translational Medicine. 2018 Sept;4(3):176–86. doi:10.1016/j.cdtm.2018.07.002
6. Xing Y, Xu Y, Shi M, Lian Y. The impact of PM2.5 on the human respiratory system. Journal of Thoracic Disease. 2016 Jan;8(1):E69–74. doi:10.3978/j.issn.2072-1439.2016.01.19
7. Basith S, Manavalan B, Shin TH, Park CB, Lee W-S, Kim J, et al. The Impact of Fine Particulate Matter 2.5 on the Cardiovascular System: A

Review of the Invisible Killer. Nanomaterials. 2022 Aug 2;12(15):2656. doi:10.3390/nano12152656

8. Krittanawong C, Qadeer YK, Hayes RB, Wang Z, Thurston GD, Virani S, et al. PM2.5 and cardiovascular diseases: State-of-the-Art review. International Journal of Cardiology Cardiovascular Risk and Prevention. 2023 Dec;19:200217. doi:10.1016/j.ijcrp.2023.200217
9. Marynowski M. Role of environmental pollution in irritable bowel syndrome. World Journal of Gastroenterology. 2015 Oct 28;21(40):11371. doi:10.3748/wjg.v21.i40.11371
10. Mutlu EA, Comba IY, Cho T, Engen PA, Yazıcı C, Soberanes S, et al. Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome. Environmental Pollution. 2018 Sept;240:817–30. doi:10.1016/j.envpol.2018.04.130
11. Ding S, Sun S, Ding R, Song S, Cao Y, Zhang L. Association between exposure to air pollutants and the risk of inflammatory bowel diseases visits. Environmental Science and Pollution Research. 2021 Oct 20;29(12):17645–54. doi:10.1007/s11356-021-17009-0
12. Xu W, Wang S, Jiang L, Sun X, Wang N, Liu X, et al. The influence of PM2.5 exposure on kidney diseases. Human Experimental Toxicology. 2022 Jan;41:096032712110699. doi:10.1177/09603271211069982
13. Zhang Y, Liu D, Liu Z. Fine Particulate Matter (PM2.5) and Chronic Kidney Disease. Reviews of Environmental Contamination and Toxicology Volume 254. 2021;183–215. doi:10.1007/398_2020_62

14. He D, Wu S, Zhao H, Qiu H, Fu Y, Li X, et al. Association between particulate matter 2.5 and diabetes mellitus: A meta-analysis of cohort studies. Journal of Diabetes Investigation. 2017 May 3;8(5):687–96. doi:10.1111/jdi.12631
15. Chilian-Herrera OL, Tamayo-Ortiz M, Texcalac-Sangrador JL, Rothenberg SJ, López-Ridaura R, Romero-Martínez M, et al. PM2.5 exposure as a risk factor for type 2 diabetes mellitus in the Mexico City metropolitan area. BMC Public Health. 2021 Nov 13;21(1). doi:10.1186/s12889-021-12112-w
16. Mohamed EF, Awad G. Development of nano-sensor and Biosensor as an air pollution detection technique for the foreseeable future. Environmental Nanotechnology: Implications and Applications. 2022 Jan 28;163–88. doi:10.1016/bs.coac.2021.11.003
17. Thangavel P, Park D, Lee Y-C. Recent insights into particulate matter (pm2.5)-mediated toxicity in humans: An overview. International Journal of Environmental Research and Public Health. 2022 Jun 19;19(12):7511. doi:10.3390/ijerph19127511
18. McDuffie EE, Martin RV, Spadaro JV, Burnett R, Smith SJ, O'Rourke P, et al. Source sector and fuel contributions to ambient PM2.5 and attributable mortality across multiple spatial scales. Nature Communications. 2021 Jun 14;12(1). doi:10.1038/s41467-021-23853-y
19. Shaddick G, Thomas ML, Mudu P, Ruggeri G, Gumy S. Half the world's population are exposed to increasing air pollution. npj Climate and Atmospheric Science. 2020 Jun 17;3(1). doi:10.1038/s41612-020-0124-2

20. Manisalidis I, Stavropoulou E, Stavropoulos A, Bezirtzoglou E. Environmental and health impacts of Air Pollution: A Review. Frontiers in Public Health. 2020 Feb 20;8. doi:10.3389/fpubh.2020.00014
21. Susanto AD. Air pollution and human health. Medical Journal of Indonesia. 2020 Mar 20;29(1):8–10. doi:10.13181/mji.com.204572
22. Snyder EG, Watkins TH, Solomon PA, Thoma ED, Williams RW, Hagler GS, et al. The changing paradigm of Air Pollution Monitoring. Environmental Science & Technology. 2013 Oct 3;47(20):11369–77. doi:10.1021/es4022602
23. First in Air Quality [Internet]. Available from: https://www.iqair.com/id/newsroom/what-is-aqi
24. AQI Basics [Internet]. AirNow.gov, U.S. EPA; Available from: https://www.airnow.gov/aqi/aqi-basics/
25. Mims JW. Asthma: definitions and pathophysiology. International Forum of Allergy & Rhinology. 2015 Sept;5(S1). doi:10.1002/alr.21609
26. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Frontiers in Pediatrics. 2019 Jun 18;7. doi:10.3389/fped.2019.00246
27. Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Seminars in Immunopathology. 2020 Feb;42(1):5–15. doi:10.1007/s00281-020-00785-1
28. Toskala E, Kennedy DW. Asthma risk factors. International Forum of Allergy & Rhinology. 2015 Sept;5(S1). doi:10.1002/alr.21557

29. Padem N, Saltoun C. Classification of asthma. Allergy and Asthma Proceedings. 2019 Nov 1;40(6):385–8. doi:10.2500/aap.2019.40.4253
30. Kuruvilla ME, Lee FE-H, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clinical Reviews in Allergy & Immunology. 2018 Sept 11;56(2):219–33. doi:10.1007/s12016-018-8712-1
31. Maslan J, Mims JW. What is Asthma? Pathophysiology, Demographics, and Health Care Costs. Otolaryngologic Clinics of North America. 2014 Feb;47(1):13–22. doi:10.1016/j.otc.2013.09.010
32. Patadia MO, Murrill LL, Corey J. Asthma: symptoms and presentation. Otolaryngologic Clinics of North America. 2014 Feb;47(1):23–32. doi:10.1016/j.otc.2013.10.001
33. Asthma: Updated Diagnosis and Management Recommendations from GINA. American Family Physician. 2020 Jun 15;101(12):762–763.
34. Zhang Y, Yin X, Zheng X. The relationship between PM2.5 and the onset and exacerbation of childhood asthma: a short communication. Frontiers in Pediatrics. 2023 Aug 1;11. doi:10.3389/fped.2023.1191852
35. Vestbo J. COPD Definition and Phenotypes. Clinics in Chest Medicine. 2014 Mar;35(1):1–6. doi:10.1016/j.ccm.2013.10.010
36. Diaz-Guzman E, Mannino DM. Epidemiology and Prevalence of Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine. 2014 Mar;35(1):7–16. doi:10.1016/j.ccm.2013.10.002
37. Kalhan R, Mannino D, Rosenberg S. Epidemiology of Chronic Obstructive Pulmonary Disease: Prevalence, Morbidity, Mortality, and Risk Factors.

Seminars in Respiratory and Critical Care Medicine. 2015 Aug 3;36(04):457–69. doi:10.1055/s-0035-1555607

38. 1. Lin JS, Webber EM, Thomas RG. Classification of COPD as Defined by Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet]. U.S. National Library of Medicine; 2022. Available from: http://www.ncbi.nlm.nih.gov/books/NBK580644/table/ch1.tab1/
39. Huang X, Mu X, Deng L, Fu A, Pu E, Tang T, et al. The etiologic origins for chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2019 May;Volume 14:1139–58. doi:10.2147/copd.s203215
40. MacNee W. Pathology, pathogenesis, and pathophysiology. BMJ. 2006 May 20;332(7551):1202–1204.
41. Marvel J, Yu T-C, Wood R, Small M, Higgins VS, Make BJ. Health Status of Patients With Chronic Obstructive Pulmonary Disease by Symptom Level. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2016;3(3):643–52. doi:10.15326/jcopdf.3.3.2015.0177
42. Tsiligianni I, Kocks JW. Daytime symptoms of chronic obstructive pulmonary disease: a systematic review. NPJ Primary Care Respiratory Medicine. 2020 Feb 21;30(1). doi:10.1038/s41533-020-0163-5
43. 1. Laisure M, Covill N, Ostroff ML, Ostroff JL. Summarizing the 2021 Updated GOLD Guidelines for COPD. US Pharmacist. 2021;46(7):30–35.
44. Wang Q, Liu S. The Effects and Pathogenesis of PM2.5 and Its Components on Chronic Obstructive Pulmonary Disease. International Journal of

Chronic Obstructive Pulmonary Disease. 2023 Apr;18:493–506. doi:10.2147/copd.s402122

45. Thakur C. An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. 2019;21–38. doi:10.1016/b978-0-12-815720-6.00002-2
46. Workman ML, Winkelman C. Genetic Influences in Common Respiratory Disorders. Critical Care Nursing Clinics of North America. 2008 Jun;20(2):171–89. doi:10.1016/j.ccell.2008.01.009
47. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Lung Cancer and Personalized Medicine. 2015 Dec 15;1–19. doi:10.1007/978-3-319-24223-1_1
48. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Translational Lung Cancer Research. 2018 Jun;7(3):220–33. doi:10.21037/tlcr.2018.05.06
49. Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. European Respiratory Journal. 2016 May 12;48(3):889–902. doi:10.1183/13993003.00359-2016
50. Zheng M. Classification and Pathology of Lung Cancer. Surgical Oncology Clinics of North America. 2016 Jul;25(3):447–68. doi:10.1016/j.soc.2016.02.003
51. Bade BC, Dela Cruz CS. Lung Cancer 2020. Clinics in Chest Medicine. 2020 Mar;41(1):1–24. doi:10.1016/j.ccm.2019.10.001

52. Jameson JL, Kasper DL, Fauci AS, Hauser SL, Longo DL, Loscalzo J, et al. Harrison's principles of Internal Medicine. 20th ed. New York: McGraw-Hill Education; 2018.
53. Latimer KM, Mott TF. Lung Cancer: Diagnosis, Treatment Principles, and Screening. American Family Physician. 2015;91(4):250–256.
54. Kim J, Lee H, Huang BW. Lung Cancer: Diagnosis, Treatment Principles, and Screening. American Family Physician. 2022 Apr 1;105(5):487–494.
55. Li R, Zhou R, Zhang J. Function of PM2.5 in the pathogenesis of lung cancer and chronic airway inflammatory diseases. Oncology Letters. 2018 Mar 26; doi:10.3892/ol.2018.8355
56. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. Nature Reviews Disease Primers. 2018 Mar 22;4(1). doi:10.1038/nrdp.2018.14
57. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nature Reviews Nephrology. 2020 Feb 5;16(4):223–37. doi:10.1038/s41581-019-0244-2
58. Guirguis-Blake JM. Blood Pressure Classifications [Internet]. U.S. National Library of Medicine; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570233/table/ch1.tab1/
59. Nadella V, Howell S. Hypertension: pathophysiology and perioperative implications. BJA Education. 2015 Dec;15(6):275–9. doi:10.1093/bjaceaccp/mkv001

60. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020 Jun;75(6):1334–57. doi:10.1161/hypertensionaha.120.15026
61. Carey RM, Moran AE, Whelton PK. Treatment of Hypertension. JAMA. 2022 Nov 8;328(18):1849. doi:10.1001/jama.2022.19590
62. Liang R, Zhang B, Zhao X, Ruan Y, Lian H, Fan Z. Effect of exposure to PM2.5 on blood pressure. Journal of Hypertension. 2014 Nov;32(11):2130–41. doi:10.1097/hjh.0000000000000342
63. Shao C, Wang J, Tian J, Tang Y. Coronary Artery Disease: From Mechanism to Clinical Practice. Advances in Experimental Medicine and Biology. 2020;1–36. doi:10.1007/978-981-15-2517-9_1
64. Malakar AKr, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. Journal of Cellular Physiology. 2019 Feb 20;234(10):16812–23. doi:10.1002/jcp.28350
65. Makarović Z. NONOBSTRUCTIVE CORONARY ARTERY DISEASE – CLINICAL RELEVANCE, DIAGNOSIS, MANAGEMENT AND PROPOSAL OF NEW PATHOPHYSIOLOGICAL CLASSIFICATION. Acta Clinica Croatica. 2018 Sept;57(3):528–541. doi:10.20471/acc.2018.57.03.17
66. Lowenstern A, Alexander KP, Pagidipati NJ, Hill CL, Pellikka PA, Cooper LS, et al. Presenting Symptoms in Patients Undergoing Coronary Artery

Disease Evaluation: Association With Noninvasive Test Results and Clinical Outcomes in the PROMISE Trial. Circulation: Cardiovascular Quality and Outcomes. 2022 May;15(5). doi:10.1161/circoutcomes.121.008298

67. Hanson MA, Fareed MT, Argenio SL, Agunwamba AO, Hanson TR. Coronary artery disease. Primary Care: Clinics in Office Practice. 2013 Mar;40(1):1–16. doi:10.1016/j.pop.2012.12.001
68. Braun MM, Stevens WA, Barstow CH. Stable Coronary Artery Disease: Treatment. American Family Physician. 2018;97(6):376–384.
69. Montone RA, Rinaldi R, Bonanni A, Severino A, Pedicino D, Crea F, et al. Impact of air pollution on ischemic heart disease: Evidence, mechanisms, clinical perspectives. Atherosclerosis. 2023 Feb;366:22–31. doi:10.1016/j.atherosclerosis.2023.01.013
70. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ (Buddy), Culebras A, et al. An Updated Definition of Stroke for the 21st Century. Stroke. 2013 Jul;44(7):2064–89. doi:10.1161/str.0b013e318296aeca
71. Puthenpurakal A, Crussell J. Stroke 1: definition, burden, risk factors and diagnosis. Nursing Times. 2017 Nov;113(11):43–7.
72. Guzik A, Bushnell C. Stroke Epidemiology and Risk Factor Management. CONTINUUM: Lifelong Learning in Neurology. 2017 Feb;23(1):15–39. doi:10.1212/con.0000000000000416
73. Murphy SJX, Werring DJ. Stroke: causes and clinical features. Medicine. 2020 Sept;48(9):561–6. doi:10.1016/j.mpmed.2020.06.002

74. Kuriakose D, Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. International Journal of Molecular Sciences. 2020 Oct 15;21(20):7609. doi:10.3390/ijms21207609
75. Yew KS, Cheng EM. Diagnosis of Acute Stroke. American Family Physician. 2015;91(8):528–536.
76. Cai M, Lin X, Wang X, Zhang S, Wang C, Zhang Z, et al. Long-term exposure to ambient fine particulate matter chemical composition and in-hospital case fatality among patients with stroke in China. The Lancet Regional Health - Western Pacific. 2023 Mar;32:100679. doi:10.1016/j.lanwpc.2022.100679
77. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nature Reviews Disease Primers. 2015 Jul 23;1(1). doi:10.1038/nrdp.2015.19
78. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The Lancet. 2017 Jun;389(10085):2239–51. doi:10.1016/s0140-6736(17)30058-2
79. Taylor R. Type 2 Diabetes: Etiology and reversibility. Diabetes Care. 2013 Mar 14;36(4):1047–55. doi:10.2337/dc12-1805
80. Good to Know: Diabetes Symptoms and Tests. Clinical Diabetes. 2020 Jan 1;38(1):108–108. doi:10.2337/cd20-pe01
81. Heck TG, Fiorin PB, Frizzo MN, Ludwig MS. Fine Particulate Matter (PM2.5) Air Pollution and Type 2 Diabetes Mellitus (T2DM): When Experimental Data Explains Epidemiological Facts. Diabetes and Its Complications. 2018 Apr 18; doi:10.5772/intechopen.70668

82. Enck P, Azpiroz F, Boeckxstaens G, Elsenbruch S, Feinle-Bisset C, Holtmann G, et al. Functional dyspepsia. Nature Reviews Disease Primers. 2017 Nov 3;3(1). doi:10.1038/nrdp.2017.81
83. Talley NJ. Functional dyspepsia: Advances in diagnosis and therapy. Gut and Liver. 2017 May 15;11(3):349–57. doi:10.5009/gnl16055
84. Yamawaki H, Futagami S, Wakabayashi M, Sakasegawa N, Agawa S, Higuchi K, et al. Management of functional dyspepsia: State of the art and emerging therapies. Therapeutic Advances in Chronic Disease. 2017 Aug 27;9(1):23–32. doi:10.1177/2040622317725479
85. Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. The Lancet. 2020 Nov 21;396(10263):1689–702. doi:10.1016/s0140-6736(20)30469-4
86. Talley NJ, Goodsall T, Potter M. Functional dyspepsia. Australian Prescriber. 2017 Dec 4;40(6):209–13. doi:10.18773/austprescr.2017.066
87. Stanghellini V, Chan FKL, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology. 2016 May;150(6):1380–92. doi:10.1053/j.gastro.2016.02.011
88. Harer KN, Hasler WL. Functional Dyspepsia: A Review of the Symptoms, Evaluation, and Treatment Options. Gastroenterology & Hepatology. 2020 Feb;16(2):66–74.
89. Sayuk GS, Gyawali CP. Functional dyspepsia: Diagnostic and therapeutic approaches. Drugs. 2020 Jul 20;80(13):1319–36. doi:10.1007/s40265-020-01362-4

90. Lee KJ. The usefulness of symptom-based subtypes of functional dyspepsia for predicting underlying pathophysiologic mechanisms and choosing appropriate therapeutic agents. Journal of Neurogastroenterology and Motility. 2021 Jul 30;27(3):326–36. doi:10.5056/jnm21042
91. Talley NJ, Powell N, Walker MM, Jones MP, Ronkainen J, Forsberg A, et al. Role of smoking in functional dyspepsia and irritable bowel syndrome: Three random population-based studies. Alimentary Pharmacology & Therapeutics. 2021 May 13;54(1):32–42. doi:10.1111/apt.16372
92. Mounsey A, Barzin A, Rietz A. Functional Dyspepsia: Evaluation and Management. American Family Physician. 2020 Jan 15;101(2):84–8.
93. Xie S, Zhang C, Zhao J, Li D, Chen J. Exposure to concentrated ambient PM2.5 (CAPM) induces intestinal disturbance via inflammation and alternation of gut microbiome. Environment International. 2022 Mar;161:107138. doi:10.1016/j.envint.2022.107138
94. Salim SY, Kaplan GG, Madsen KL. Air pollution effects on the gut microbiota. Gut Microbes. 2013 Dec 20;5(2):215–9. doi:10.4161/gmic.27251
95. Sembiring ETJ. RISIKO KESEHATAN PAJANAN PM2,5 DI UDARA AMBIEN PADA PEDAGANG KAKI LIMA DI BAWAH FLYOVER PASAR PAGI ASEMKA JAKARTA. Jurnal Teknik Lingkungan. 2020 Apr 1;26(1):101–20. doi:10.5614/j.tl.2020.26.1.7
96. Goldland Karawaci [Internet]. Available from: https://goldlandkarawaci.co.id/masterplan.php

97. Kazemi Z, Jonidi Jafari A, Farzadkia M, Amini P, Kermani M. Evaluating the mortality and health rate caused by the PM2.5 pollutant in the air of several important Iranian cities and evaluating the effect of variables with a linear time series model. Heliyon. 2024 Mar;10(6). doi:10.1016/j.heliyon.2024.e27862

98. Haryanto B, Resosoedarmo B, Utami ST, Hartono B, Hermawati E. Effect of Ambient Particulate Matter 2.5 Micrometer (PM2.5) to Prevalence of Impaired Lung Function and Asthma in Tangerang and Makassar. Kesmas: National Public Health Journal. 2016 Jun 21;10(4):145–9. doi:10.21109/kesmas.v10i4.823

99. Fan X, Yang C, Chen J, Chen Y, Chen G, Lin Z, et al. Impact of Low PM2.5 Exposure on Asthma Admission: Age-Specific Differences and Evidence from a Low-Pollution Environment in China. Aerosol and Air Quality Research. 2024;24(2):230195. doi:10.4209/aaqr.230195

100. Zheng X, Guo S, Hu J, Meng R, Xu Y, Lv Y, et al. Long-term associations of PM1 versus PM2.5 and PM10 with asthma and asthma-related respiratory symptoms in the middle-aged and elderly population. ERJ Open Research. 2024 Mar 7;10(4):00972–2023. doi:10.1183/23120541.00972-2023

101. Liu S, Zhou Y, Liu S, Chen X, Zou W, Zhao D, et al. Association between exposure to ambient particulate matter and chronic obstructive pulmonary disease: results from a cross-sectional study in China. Thorax. 2016 Dec 9;72(9):788–95. doi:10.1136/thoraxjnl-2016-208910

102. Huang F, Pan B, Wu J, Chen E, Chen L. Relationship between exposure to PM2.5 and lung cancer incidence and mortality: A meta-analysis. Oncotarget. 2017 Apr 21;8(26):43322–31. doi:10.18632/oncotarget.17313

103. Guo H, Li W, Wu J. Ambient PM2.5 and Annual Lung Cancer Incidence: A Nationwide Study in 295 Chinese Counties. International Journal of Environmental Research and Public Health. 2020 Feb 25;17(5):1481. doi:10.3390/ijerph17051481

104. Madrigano J, Yan D, Liu T, Bonilla E, Yulianti N, Mickley LJ, et al. Air Pollution and Blood Pressure: Evidence From Indonesia. GeoHealth. 2024 Jul;8(7). doi:10.1029/2024gh001014

105. Du Y, Xu X, Chu M, Guo Y, Wang J. Air particulate matter and cardiovascular disease: the epidemiological, biomedical and clinical evidence. Journal of Thoracic Disease. 2016 Jan 30;8(1). doi:10.3978/j.issn.2072-1439.2015.11.37

106. Kim H, Kim J, Kim S, Kang S, Kim H, Kim H, et al. Cardiovascular Effects of Long-Term Exposure to Air Pollution: A Population-Based Study With 900 845 Person-Years of Follow-up. Journal of the American Heart Association. 2017 Nov;6(11). doi:10.1161/jaha.117.007170

107. Gestro M, Condemi V, Bardi L, Tomaino L, Roveda E, Bruschetta A, et al. Short-term air pollution exposure is a risk factor for acute coronary syndromes in an urban area with low annual pollution rates: Results from a

retrospective observational study (2011–2015). Archives of Cardiovascular Diseases. 2020 May;113(5):308–20. doi:10.1016/j.acvd.2020.03.013

108. Zhang J, Wang X, Yan M, Shan A, Wang C, Yang X, et al. Sex Differences in Cardiovascular Risk Associated With Long-Term PM2.5 Exposure: A Systematic Review and Meta-Analysis of Cohort Studies. Frontiers in Public Health. 2022 Feb 2;10. doi:10.3389/fpubh.2022.802167

109. O'Donnell MJ, Fang J, Mittleman MA, Kapral MK, Wellenius GA. Fine Particulate Air Pollution (PM2.5) and the Risk of Acute Ischemic Stroke. Epidemiology. 2011 May;22(3):422–31. doi:10.1097/ede.0b013e3182126580

110. Bo Y, Zhu Y, Zhang X, Chang H, Zhang J, Lao XQ, et al. Spatiotemporal Trends of Stroke Burden Attributable to Ambient PM2.5 in 204 Countries and Territories, 1990–2019. Neurology. 2023 Aug 15;101(7):e764–76. doi:10.1212/wnl.0000000000207503

111. Suryadhi MA, Suryadhi PA, Abudureyimu K, Ruma IM, Calliope AS, Wirawan DN, et al. Exposure to particulate matter (PM2.5) and prevalence of diabetes mellitus in Indonesia. Environment International. 2020 Jul;140:105603. doi:10.1016/j.envint.2020.105603

112. Okafor PN, Dahlen A, Youssef M, Olayode A, Sonu I, Neshatian L, et al. Environmental Pollutants Are Associated With Irritable Bowel Syndrome in a Commercially Insured Cohort of California Residents. Clinical Gastroenterology and Hepatology. 2023 Jun;21(6):1617–26. doi:10.1016/j.cgh.2022.09.025